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The delineation of dopamine dysfunction in the mentally ill has
been a long-standing quest of biological psychiatry. The present
study focuses on a recently recognized group of dopamine recep-
tor-interacting proteins as possible novel sites of dysfunction in
schizophrenic and bipolar patients. We demonstrate that the
dorsolateral prefrontal cortex in schizophrenia and bipolar cases
from the Stanley Foundation Neuropathology Consortium display
significantly elevated levels of the D2 dopamine receptor desen-
sitization regulatory protein, neuronal calcium sensor-1. These
levels of neuronal calcium sensor-1 were not influenced by age,
gender, hemisphere, cause of death, postmortem period, alcohol
consumption, or antipsychotic and mood stabilizing medications.
The present study supports the hypothesis that schizophrenia and
bipolar disorder may be associated with abnormalities in dopamine
receptor-interacting proteins.
Abnormalities in the brain’s dopamine system have beenpostulated for both schizophrenia (SCHIZ) and bipolar
disorder (BPD) (1–4). However, in both cases, the exact sites of
alterations in this system have remained elusive. The traditional
focus on the regulation of dopamine and its receptors has been
giving way in recent years to an increasing interest in intracellular
signaling cascades and molecules (5–7). In particular, recent
discoveries of multiple dopamine receptor-interacting proteins
(DRIPs) and evidence of their role in modifying and expanding
the functionality of these receptors has led us to hypothesize
that abnormalities in the dopamine systems of SCHZ and
BPD patients might lie in altered levels of certain DRIPs in
specific areas of the brain (8–11). By using tissue from SCHIZ,
BPD, major depression (MD), and normal control (NC) indi-
viduals provided to us by the Stanley Foundation Neuropathol-
ogy Consortium, we have previously demonstrated that the
dorsolateral prefrontal cortex (DLPFC) of SCHIZ patients
expresses nearly twice the normal levels of the D1 DRIP protein,
calcyon (12).
The present paper describes examinations of another DRIP,
neuronal calcium sensor 1 (NCS-1), in the same tissue samples.
NCS-1 belongs to the recoverin subfamily of EF-hand Ca2-
binding proteins (13) and is present in neuronal cells throughout
the brain (14–17). It has been shown that this protein can form
complexes with G-protein-coupled receptor kinase-2 (GRK2)
and D2 dopamine receptor (DR2), and, in doing this, prevents
GRK2-mediated desensitization of activated DR2 (11). The
regulation of DR desensitization is not the only reported activity
of this protein. Among the major actions of NCS-1 and its
Drosophilae orthologue, frequenin, are regulation of exocytosis
of secretory and neurotransmitter substances (18–22), control of
trafficking of cellular proteins (23, 24), and modulation of the
activity of K and Ca2 ionic channels (25–27). In addition,
up-regulation of the NCS-1 gene has been observed in the rat
dentate gyrus after long-term potentiation, suggesting that this
protein may be involved in activity-dependent neuronal plasticity
(28). Here, we report that the levels of NCS-1 are significantly
elevated in the DLPFC of SCHIZ and BPD patients. This finding
supports our hypothesis that SCHIZ and BPD may be associated
with altered levels of brain DRIPs.
Materials and Methods
The samples of human DLPFC (area 46 of Brodmann; ref. 29)
of NC, schizophrenic, BPD and MD cases (n  15 per group)
were obtained from the Stanley Foundation Neuropathology
Consortium. The DLPFC was chosen for analysis as displaying
one of the highest NCS-1 expression levels in the brain (17).
This region has also been identified as a site of dysfunction in
both SCHIZ and affective disorders (reviewed in refs. 30 and
31). The demographic, clinical, and storage characteristics for
cases constituting the Consortium have been published (32,
33). The diagnostic groups were matched according to age,
race, gender, mean postmortem interval, pH, and hemisphere.
Each sample was received as a set of six consecutive 40-m-
thick cryostat-cut frozen sections, which were maintained
frozen after the sectioning. The cortical tissue from five
sections per sample was cut out and homogenized for use in
slot blot analysis. The sixth section from each sample was
stained with cresyl violet and used for estimation of the
proportion of neuronal cells within the cortex. All of the
analyses in this study were performed in a blind manner, with
the diagnosis of the cases being revealed to the investigators
only after all of the data were collected.
Samples of monkey DLPFC (area 46 of Brodmann; ref. 29)
were obtained from five drug-naı̈ve control and five haloperidol-
treated rhesus monkeys. The latter animals received 0.175 mgkg
haloperidol orally twice a day for a period of 6–8 months.
Previously we demonstrated that such treatment results in
up-regulation of DR2s and down-regulation of DR1s in DLPFC
(34). A portion of the dissected tissue was homogenized as
described above for the human samples. The other part was
frozen, sectioned on a cryostat into 40-m-thick sections, and
processed for cresyl violet staining.
Levels of NCS-1 in the sample homogenates were evaluated
by using slot blots on NitroPure membranes (Osmonics,
Minnetonka, MN) prepared with Bio-Dot SF Microfiltration
Apparatus (Bio-Rad) as described (12, 35). We generated a total
of 15 membranes from the human material, each containing
blots of 12 samples in triplicates. Therefore, each of the 60
human samples used in this study was blotted on three different
membranes. In addition, we produced three membranes, each of
containing triplicate slots of all 10 nonhuman primate samples
examined in this study. All membranes also included six slots of
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specially prepared ‘‘standard’’ homogenates of the human
DLPFC containing a range of known amounts of total protein.
Finally, each membrane included three slots made with pure
tissue homogenization buffer and three slots made with BSA
prepared as tissue samples, to control for nonspecific back-
ground staining.
Before immunostaining, each membrane was stained with
SYPRO Rose Plus stain (Molecular Probes), which visualized
the total protein within each slot blot. The staining was
observed with a UV Photo Viewer Illumination System (Ultra-
Lum, Claremont, CA) at a 365-nm wavelength (Fig. 1A). The
f luorescent images of blots were digitized for densitometric
analysis with a Universal Software (Advanced American Bio-
technology, Fullerton, CA), and the total protein levels in
sample slot blots were calculated by comparing the intensities
of their staining with those of the above-mentioned six slots of
the ‘‘standard’’ tissue homogenates. The immunostaining of
the membranes included incubation with the primary chicken
anti-frequenin antibodies (1:1,000 dilution; Rockland, Gil-
bertsville, PA) overnight at 4°C, which was followed by 1.5 h
exposure at room temperature to horseradish peroxidase-
conjugated donkey antichicken secondary antibodies (1:5,000
dilution; Jackson ImmunoResearch). Visualization of labeling
was conducted with the Super Signal Chemiluminescence
Substrate (Pierce) and X-Omat AR Film (Kodak). The spec-
ificity of this immunolabeling was evaluated by Western blots
of three randomly selected samples from all cases used in the
present study. As expected, the immunolabeling visualized a
single 22-kDa band (Fig. 1C), which is the molecular mass of
NCS-1 (13, 15). The generated film images of NCS-1-specific
immunolabeling were digitized (Fig. 1B) and processed for
densitometry, which assessed the levels NCS-1 in sample slot
blots by comparing the gray value of the images of these blots
with those of the six blots of the ‘‘standard’’ tissue homoge-
nates. Levels of NCS-1 in the sample blots were calculated
in equivalents of ng of the total protein in the blots of the
‘‘standard’’ homogenate producing the immunolabeling of the
same intensity. Based on the estimations of total protein and
the specific protein in each blot, we were able to express NCS-1
levels per nanogram of total protein in a given sample.
NCS-1 is a neuronal protein (11, 15, 16). This prompted us to
try and express its levels per cortical neuron. Because it is not
possible to determine precisely the number of neurons in the
tissue samples used for blots, the closest representation of the
quantity of a given protein per neuron is to express the levels of
this protein per ng of neuronal DNA (35). For this purpose, we
divided the mean levels of specific proteins in the protein slot
blots from a given sample by the mean levels of DNA in the DNA
slot blots from this sample and multiplied by the mean propor-
tion of neurons in a section from the same tissue.
The DNA slot blots were produced as described (12, 35). They
were generated on a set of Hybond-N Nylon membranes
(Amersham Pharmacia) with every membrane containing slots
of 12 samples in triplicates. As in the case of the blots for protein
analysis, each of the 60 samples used in this study was blotted on
three different membranes. All membranes also included a set
of six ‘‘standard’’ blots containing a range of known amounts
of salmon sperm DNA (Sigma), and six ‘‘background’’ slots of
BSA. The slots were stained with SYBR DX DNA-specific Blot
Stain (Molecular Probes). The staining was visualized at the
wavelength of 254 nm and digitized. The digitized images were
processed for densitometry and the amounts of DNA in sample
blots were estimated by comparing the intensities of their
staining with those of the above-mentioned six blots of the DNA
standards.
The proportion of neurons in sections from each case was
estimated by 3D cell counting as outlined in refs. 12 and 35. For
each section, the counting was performed in five non-
overlapping randomly selected counting boxes (55-m width 
8-m depth) stretching across the entire thickness of the cerebral
cortex from the pial surface to the white matter. The total
number of cell nuclei and the number of neuronal nuclei were
obtained for every counting box and then the mean proportion
of neurons among the total cell nuclei was calculated for each
case. Neuronal nuclei were identified based on the criteria of
Selemon et al. (36). Cell counting was performed solely to
determine the proportions of neurons in the tissue samples
needed for calculation of the levels of specific proteins per
neuronal DNA. The mean percentages of neuronal nuclei in
sections of dorsolateral prefrontal cortex from schizophrenic,
bipolar, and major depressive groups were within 5% of the
mean proportion of neuronal nuclei in sections from the control
Fig. 1. Representative examples of the images of slot blots and Western blots
generated in this study. (A) Typical fluorescent image of a membrane with slot
blots stained for the total protein. (B) Film image of the same membrane
resulted from NCS-1-specific immunolabeling. In both A and B, 1–12 are
triplicate blots from different tissue samples. Six ‘‘standard’’ blots were made
from the specially prepared human LDPFC homogenates with known amounts
of the total protein. The background blots contain either pure homogeniza-
tion buffer or BSA. (C) Typical film image produced by NCS-1 immunostaining
of Western blot of human LDPFC. The image contains only a single band of
22 kDa, which is the molecular mass of NCS-1.
Table 1. Percentage of neurons in samples of the DLPFC from the Stanley Foundation
Neuropathology Consortium
Groups NC SCHIZ BPD MD
% neurons among all cells  SD 39.95  7.4 44.62  9.7 40.09  8.9 42.01  7.1
Differences between % of neurons
in disease groups and control  SD
4.67  8.2 0.14  7.4 2.06  6.3
Each group consists of 15 cases.
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group (Table 1), and also in agreement with previous reports
(37–39). Also in agreement with our previous study (12), halo-
peridol produced less than a 3% change in the proportion of
neurons in the dorsolateral prefrontal cortex of monkeys treated
with haloperidol relative to drug-naı̈ve monkeys.
A statistical comparison of NCS-1 levels between different
diagnostic groups was conducted by a one-way ANOVA fol-
lowed by a Dunnett’s post hoc comparison between controls and
each of the mental disease groups. One-way ANOVAs were also
used to evaluate whether levels of NCS-1 are influenced by cause
of death (cardiopulmonary diseaseaccidentsuicide) or alcohol
consumption (no or light usemoderate useheavy use; the
definitions are given in Table 2). In addition, one-way ANOVA
was used for comparison of the effects of treatments with
antipsychotic, mood stabilizing, and a combination of antipsy-
choticmood stabilizing drugs at the time of death. Correlation
analysis was used for examination of possible influences of age,
lifetime fluphenazine equivalent, postmortem interval, and
brain pH. The effect of gender and hemisphere in the human
cases and the effect of haloperidol treatment in nonhuman
primates were assessed with two-tailed Student’s t tests. Because,
among all of the cases examined, all but four were Caucasians,
no examination of the effects of race was performed. This study
included too few non-alcohol drug abusers (with different
individuals abusing different drugs) to allow a meaningful
evaluation of the possible effects of drug abuse.
Results and Discussion
Increase of NCS-1 in DLPFC of SCHIZ and BPD Patients. We found that
the DLPFC of SCHIZ and BPD patients displayed 50% higher
levels of NCS-1 compared with the same cortical region of NC
individuals (Fig. 2). This increase was observed regardless of
whether the data were expressed per total tissue protein or per
neuronal DNA, which suggests that they are likely to reflect a
specific up-regulation of this protein, rather than nonspecific
difference in total protein or neuronal density between the
groups examined in this study. In contrast, no significant differ-
ences were detected in DLPFC levels of NCS-1 between NC and
MD groups (Fig. 2).
To determine whether the observed elevations of NCS-1 levels
in SCHIZ and BPD groups were related to the effect of
medications, we compared the levels of NCS-1 in SCHIZ and
BPD patients maintained at the time of death on antipsychotic
andor mood stabilizing drugs with the levels of this protein in
drug-free cases from the same two groups. This comparison was
Fig. 2. Plots of the levels of NCS-1 (expressed per nanogram of total
protein and per nanogram of neuronal DNA) in the DLPFC from NC, SCHIZ,
BPD, and MD groups of the Stanley Foundation Neuropathology Consor-
tium. Each group in the consortium  15 cases. Circles represent the data
from individual samples. The horizontal lines represent the mean values for
the group. Vertical lines represent SD. P  statistical significance of Dun-
nett’s post hoc one-way ANOVA comparison of the levels of NCS-1 between
NC and a given mental disease group (P for the ANOVAs preceding the
Dunnett’s tests: 0.007 for NCS-1 expressed per total protein and 0.001 for
NCS-1 expressed per neuronal DNA). The statistically significant increases in
NCS-1 levels (marked by asterisks) as compared with controls are seen in
SCHIZ and BPD groups.
Fig. 3. Histogram showing the DLPFC levels of NCS-1 in SCHIZ and BPD
patients from the Stanley Foundation Neuropathology Consortium who at
the time of death received either no medications, antipsychotic drugs, mood-
stabilizing drugs, or a combination of these drugs. Each column represents the
mean  SD. No statistically significant differences are present (P of one-way
ANOVA  0.407). DF, drug free; AS, antipsychotic medication; MS, mood-
stabilizing medications.
Table 2. Effects of gender, hemisphere, most frequent causes of death, and alcohol
consumption among the cases of the Stanley Foundation Neuropathology Consortium
on NCS-1 levels in the DLPFC expressed per ng of neuronal DNA
Parameters Groups Mean  SD P
Gender Males (n  36) 24.24  14.72 0.848 (t test)
Females (n  24) 23.56  10.89
Hemisphera Right (n  27) 24.13  14.60 0.926 (t test)
Left (n  33) 23.80  11.75
Cause of death Cardiopulmonary (n  32) 22.39  13.69 0.808 (one-way ANOVA)
Accident (n  4) 22.95  13.45
Suicide (n  20) 24.87  12.74
Alcohol consumption at
the time of death*
Nonelight (n  48) 22.02  11.77 0.619 (one-way ANOVA)
Moderate (n  5) 26.20  9.94
Heavy (n  7) 25.91  16.03
Note that the levels of calcyon are not affected by any of these parameters.
*Moderate alcohol use: one to two drinks a day; heavy alcohol use: more than one to two drinks a day; light
alcohol use: less than one drink a day.








not statistically significant, indicating that the observed NCS-1
abnormalities were not caused by medication (Fig. 3). Further-
more, comparison of NCS-1 levels in DLPFC of drug-naı̈ve and
chronic haloperidol-treated monkeys failed to reveal significant
differences (level of NCS-1 per neuronal DNA  SD in halo-
peridol-treated monkeys was 21.26  4.03, whereas in control
animals this level was 19.43  3.53; P of two-tailed t test is 0.747).
In addition, we found that NCS-1 levels were not affected by
gender, hemisphere, causes of death, or by alcohol consumption
(Table 2). Furthermore, levels of this protein were not correlated
with lifetime consumption of antipsychotic medications (in
fluphenazine equivalents), age of the individuals included in the
study, and the length of the postmortem interval (Fig. 4). Other
than diagnosis, the only additional parameter predictive of
changes in NCS-1 was the pH of the brain tissue, with the levels
of this protein being negatively correlated with increase in tissue
alkalinity (Fig. 4). This, however, does not negate the role of
diagnosis as a predictor of NCS-1 levels because, as was men-
tioned earlier, the diagnostic groups used in this study were
matched for values of brain pH.
Possible Consequence of Increase in NCS-1. The observation that
SCHIZ and BPD patients display similar changes in NCS-1 is in
agreement with the recent observation of Knable et al. (33) that
these two disorders seem to share many biochemical abnormal-
ities. Presumably, this is a reflection of certain overlap of
symptomatic clusters constituting SCHIZ and BPD diagnoses
(40, 41). It is also notable that, in contrast to the majority of
reports of decreased expression of specific markers in brains of
SCHIZ and BPD patients (33, 42), our findings point to a
significant increase in the levels of NCS-1 in these two diseases.
It is tempting to speculate that such an increase indicates that
NCS-1 is actively involved in producing the SCHIZ- and BPD-
associated disorganization of brain functionality.
As mentioned, NCS-1 attracted our attention as a DRIP
involved in suppression of desensitization of DR2s (11), which
decreases the rate of deactivation and internalization of these
receptors and, thus, enhances their influence on cell activity (43).
Based on DR2 involvement in inhibition of DLPFC activity
(44–46), the observed NCS-1 up-regulation might be expected
to result in decreased activation of the DLPFC in SCHIZ and
BPD patients. Furthermore, this could occur without any de-
tectable change in the level of DR2s. This prediction closely
matches the observations of decreased activity of the DLPFC in
SCHIZ and BPD (47, 48) without detectable alterations in the
levels of DR2 sites in this region (49).
Non-DRIP actions of NCS-1 also need to be considered. It
is possible that the over-expression of this protein may affect
signal processing in the DLPFC in SCHIZ and BPD patients
by promoting the A-type K current (25), affecting the activity
of PQ-type Ca2 channels (26, 27) and facilitating synaptic
neurotransmitter release (20, 22). An increase in the K
current involved in membrane outward rectification would
prevent DLPFC neurons from reaching firing threshold (50).
Similar to the over-activation of DR2, this would result in
depression of DLPFC activity. There have been reports of both
NCS-1-induced decreases (26) and NCS-1-induced increases
(27) in the activity of PQ-type Ca2 channels. Nevertheless,
any change in Ca2 current would interfere with the normal
functional activity of the DLPFC. As far as neurotransmission
is concerned, the overall functional consequence of NCS-1
up-regulation would depend on the balance of the resultant
elevations in the release of inhibitory and excitatory neuro-
transmitters in the DLPFC of SCHIZ and BPD patients. It is
also interesting that a possible NCS-1 up-regulation-associated
increase in neurotransmission in the DLPFC of SCHIZ pa-
tients would take place on the background of a deficit in
neuropil, which likely is associated with decline in neuronal
connectivity (51–54). In this case, NCS-1 up-regulation may in
part provide a compensatory response for the SCHIZ-induced
neuronal connectivity decline. Up-regulation of NCS-1 may
also interfere with posttranslational trafficking of certain
proteins, which would affect the intracellular positioning and,
ultimately, the levels of these proteins (23, 24). Abnormal
positioning andor levels have been reported for numerous
synaptic, cytoskeletal, and other proteins in the DLPFC of
SCHIZ and BPD patients. It is possible that some of these
changes are related to NCS-1 up-regulation.
SCHIZ and BPD as Consequences of Disturbances in Ca2 Signaling.
The present study not only supports our original hypothesis
that SCHIZ and BPD may be associated with alterations in
DRIPs, but also adds NCS-1 to a growing list of Ca2-binding
proteins, such as visinin-like protein-1, Ca2-calmodulin-
dependent kinase II, calbindin, parvalbumin, and S100B,
which have been shown to exhibit abnormal expression in the
brain of SCHIZ andor BPD patients (55–61). In addition, in
SCHIZ brains, abnormalities have been detected in Ca2-
stimulated phosphoinositide turnover, Ca2 channels (33), and
the Ca2-release-activating DRIP, calcyon (12), whereas al-
tered levels of Ca2 were described in lymphoblasts of BPD
patients (62, 63). Such findings point to an intriguing possi-
bility: although SCHIZ and BPD can be induced by multifac-
torial causes, these causes may eventually disturb Ca2 signal-
ing, which, in this case, would constitute the central mechanism
underlying abnormal brain functionality in both diseases. The
differences between SCHIZ and BPD might then be deter-
mined by constellations of abnormalities in Ca2-associated
intracellular cascades.
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Fig. 4. Plots of correlation analyses of the levels of NCS-1 in the DLPFC
expressed per neuronal DNA in relation to age, postmortem period
(PMI), brain pH, and the lifetime dosage of antipsychotic drugs in fluphen-
azine equivalents among the cases constituting the Stanley Foundation
Neuropathology Consortium. Circles represent values for individual
samples. R  correlation coefficient; P  significance. There are no sig-
nificant correlations between NCS-1 levels and age, PMI, brain pH, and
the lifetime dosage of antipsychotic drugs. In contrast, there is a significant
negative correlation between the levels of NCS-1 and tissue alkalinity
(indicated by the descending line and the asterisk near the appropriate
P value).
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